FLOMENBERG NEAL (Chief Scientific Officer) sold 5.0% of their position (213.82K shares) of TEVOGEN BIO HOLDINGS INC. on the open market
Open‑market sale worth $250.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/6/2025ACC: 0001062993-25-004850
Officer· Chief Scientific Officer
Since Feb 2024
-213.82K
Net shares
Net seller
$250.0K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
213.82K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−14.64K
Price / share
$1.28
Trade value
$18.74K
% of position
0.3%
3/4/2025
4.25M→4.24M
Common Stock
Direct
Shares
−110.66K
Price / share
$1.21
Trade value
$133.90K
% of position
2.6%
3/5/2025
4.24M→4.13M
Common Stock
Direct
Shares
−88.52K
Price / share
$1.10
Trade value
$97.37K
% of position
2.1%
3/6/2025
4.13M→4.04M
Total
Net shares
−213.82K
Net value
-$250.01K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/4/2025 | S · Sale | −14.64K | $1.28 | $18.74K | 0.3% | 4.25M | 4.24M |
| Common Stock Direct | 3/5/2025 | S · Sale | −110.66K | $1.21 | $133.90K | 2.6% | 4.24M | 4.13M |
| Common Stock Direct | 3/6/2025 | S · Sale | −88.52K | $1.10 | $97.37K | 2.1% | 4.13M | 4.04M |
| Total | −213.82K | -$250.01K | ||||||
Derivative Transactions0
No derivative transactions reported